Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) open the trading on Wednesday, with great promise as it jumped 7.36% to $24.2, before settling in for the price of $22.54 at the close. Taking a more long-term approach, RARE posted a 52-week range of $18.41-$46.50.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 2.45%. Meanwhile, its Annual Earning per share during the time was 2.45%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 9.88%. This publicly-traded company’s shares outstanding now amounts to $96.27 million, simultaneously with a float of $89.77 million. The organization now has a market capitalization sitting at $2.33 billion. At the time of writing, stock’s 50-day Moving Average stood at $32.39, while the 200-day Moving Average is $32.91.
Ultragenyx Pharmaceutical Inc (RARE) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Ultragenyx Pharmaceutical Inc’s current insider ownership accounts for 6.95%, in contrast to 99.10% institutional ownership. According to the most recent insider trade that took place on Jan 02 ’26, this organization’s Chief Financial Officer sold 3,150 shares at the rate of 22.84, making the entire transaction reach 71,946 in total value, affecting insider ownership by 91,996.
Ultragenyx Pharmaceutical Inc (RARE) Earnings and Revenue Records
Ultragenyx Pharmaceutical Inc’s EPS increase for this current 12-month fiscal period is 9.88% and is forecasted to reach -3.94 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 40.20% through the next 5 years, which can be compared against the 2.45% growth it accomplished over the previous five years trading on the market.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Trading Performance Indicators
Let’s observe the current performance indicators for Ultragenyx Pharmaceutical Inc (RARE). It’s Quick Ratio in the last reported quarter now stands at 1.74. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 3.70.
In the same vein, RARE’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -5.94, a figure that is expected to reach -1.15 in the next quarter, and analysts are predicting that it will be -3.94 at the market close of one year from today.
Technical Analysis of Ultragenyx Pharmaceutical Inc (RARE)
[Ultragenyx Pharmaceutical Inc, RARE] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 29.54% While, its Average True Range was 35.32.
Raw Stochastic average of Ultragenyx Pharmaceutical Inc (RARE) in the period of the previous 100 days is set at 26.96%, which indicates a major fall in contrast to 34.66% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 1.47 that was higher than 1.32 volatility it exhibited in the past 100-days period.
